WLF DEPOSITION OF FDA COMMISSIONER KESSLER IS JUSTIFIED BY "DIRECT" INVOLVEMENT WITH CME POLICY, FOUNDATION ARGUES; COURT RULING ON ISSUE EXPECTED IN MAY
This article was originally published in The Gray Sheet
Executive Summary
FDA Commissioner David Kessler's "direct, active role" in formulating the agency's draft policy on industry-sponsored continuing medical education makes him eligible for deposition, the Washington Legal Foundation says in a motion recently filed in the U.S. District Court for the District of Columbia as part of its suit against the policy. The motion says that "given Dr. Kessler's intimate personal involvement in the issues giving rise to this suit, WLF is entitled to question him regarding his knowledge of those issues."
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.